Literature DB >> 11032851

Developing aptamers into therapeutics.

R R White1, B A Sullenger, C P Rusconi.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 11032851      PMCID： PMC314350          DOI： 10.1172/JCI11325

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  34 in total

1.  Blocking the initiation of coagulation by RNA aptamers to factor VIIa.

Authors:  C P Rusconi; A Yeh; H K Lyerly; J H Lawson; B A Sullenger
Journal:  Thromb Haemost       Date:  2000-11       Impact factor: 5.249

2.  Intimal hyperplasia recurs after removal of PDGF-AB and -BB inhibition in the rat carotid artery injury model.

Authors:  O Leppänen; N Janjic; M A Carlsson; K Pietras; M Levin; C Vargeese; L S Green; D Bergqvist; A Ostman; C H Heldin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-11       Impact factor: 8.311

Review 3.  Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics.

Authors:  N Usman; L M Blatt
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

Review 4.  Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function.

Authors:  L M Khachigian
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

Review 5.  Therapeutic applications of transcription factor decoy oligonucleotides.

Authors:  M J Mann; V J Dzau
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

6.  Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication.

Authors:  B A Sullenger; H F Gallardo; G E Ungers; E Gilboa
Journal:  Cell       Date:  1990-11-02       Impact factor: 41.582

7.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase.

Authors:  C Tuerk; L Gold
Journal:  Science       Date:  1990-08-03       Impact factor: 47.728

8.  In vitro selection of RNA molecules that bind specific ligands.

Authors:  A D Ellington; J W Szostak
Journal:  Nature       Date:  1990-08-30       Impact factor: 49.962

9.  Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.

Authors:  M J Mann; A D Whittemore; M C Donaldson; M Belkin; M S Conte; J F Polak; E J Orav; A Ehsan; G Dell'Acqua; V J Dzau
Journal:  Lancet       Date:  1999-10-30       Impact factor: 79.321

10.  Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor.

Authors:  D Jellinek; L S Green; C Bell; C K Lynott; N Gill; C Vargeese; G Kirschenheuter; D P McGee; P Abesinghe; W A Pieken
Journal:  Biochemistry       Date:  1995-09-12       Impact factor: 3.162
View more
  82 in total

1.  Escort aptamers: a delivery service for diagnosis and therapy.

Authors:  B J Hicke; A W Stephens
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

Review 2.  Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function.

Authors:  L M Khachigian
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

Review 3.  Therapeutic applications of transcription factor decoy oligonucleotides.

Authors:  M J Mann; V J Dzau
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

4.  Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEX.

Authors:  Axel Vater; Florian Jarosch; Klaus Buchner; Sven Klussmann
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

5.  Targeting a KH-domain protein with RNA decoys.

Authors:  Aleksandr V Makeyev; Dawn L Eastmond; Stephen A Liebhaber
Journal:  RNA       Date:  2002-09       Impact factor: 4.942

Review 6.  Protein-binding oligonucleotides: the next frontier in antithrombotic therapy.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2004-04       Impact factor: 2.300

Review 7.  Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.

Authors:  Khaled S Allemailem; Ahmad Almatroudi; Mohammed A Alsahli; Ghaiyda Talal Basfar; Faris Alrumaihi; Arshad Husain Rahmani; Amjad Ali Khan
Journal:  3 Biotech       Date:  2020-11-24       Impact factor: 2.406

8.  High-affinity aptamers to subtype 3a hepatitis C virus polymerase display genotypic specificity.

Authors:  Louisa A Jones; Leighton E Clancy; William D Rawlinson; Peter A White
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

9.  Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1.

Authors:  Laurent Chaloin; Maik Jörg Lehmann; Georg Sczakiel; Tobias Restle
Journal:  Nucleic Acids Res       Date:  2002-09-15       Impact factor: 16.971

Review 10.  Aptamers and the next generation of diagnostic reagents.

Authors:  Varatharasa Thiviyanathan; David G Gorenstein
Journal:  Proteomics Clin Appl       Date:  2012-12       Impact factor: 3.494
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.